Brand name: Abecma
Aminolevulinic acid (ALA or Levulan) is a drug that experts put right on the skin. They use it to treat actinic keratosis (AK), a skin condition that can become cancer. However, one must only use it on the face or scalp. A special blue light, rather than laser light, activates this drug.
Use of Idecabtagene Vicleucel in Cancer Treatment
Experts have authorized Idecabtagene vicleucel to treat the following conditions:
Multiple myeloma that has relapsed or is resistant to therapy (does not respond to treatment). Doctors give it to people who’ve had at least four prior therapies, including immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies.
Idecabtagene vicleucel is exclusively accessible as part of the Abecma REMS program.
A formulation of autologous peripheral blood T lymphocytes (PBTLs) that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), which may have immunostimulatory and anticancer properties. Idecabtagene vicleucel identifies and kills BCMA-expressing tumour cells immediately after delivery. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumour necrosis factor receptor superfamily (TNFRSF) and plays an important role in plasma survival; it is found on plasma cell surfaces and overexpressed on malignant plasma cells.
Idecabtagene Vicleucel – MedlinePlus Information– A summary of key facts regarding this medication in layman’s terms, which may contain the following:
Cautions about this medicine; what are its uses and how to use it; what you should tell your doctor before taking it; things you should know about it before using it; other drugs that might interact with it; and possible negative effects.
Experts frequently investigate drugs to see whether they can treat or prevent conditions other than those with authorization. This patient information leaflet only covers authorized uses of the medications. However, much of the material might also apply to authorized uses under investigation.